[Main characteristics of the treatment of liver cirrhosis].
D000293:Adolescent; D000328:Adult; D001201:Ascites / Q000628:therapy; D001510:Bed Rest; D001815:Bloodletting; D002648:Child; D002675:Child, Preschool; D002792:Cholestyramine Resin / Q000627:therapeutic use; D004041:Dietary Fats; D004044:Dietary Proteins / Q000009:adverse effects; D004232:Diuretics / Q000627:therapeutic use; D002149:Energy Intake; D005260:Female; D006432:Hemochromatosis / Q000628:therapy; D006501:Hepatic Encephalopathy / Q000628:therapy; D006527:Hepatolenticular Degeneration / Q000628:therapy; D006801:Humans; D007792:Lactulose / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000628:therapy*; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D011188:Potassium / Q000378:metabolism; D014805:Vitamin B 12 / Q000627:therapeutic use
D004041:Dietary Fats; D004044:Dietary Proteins; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D002792:Cholestyramine Resin; D007792:Lactulose; D010396:Penicillamine; D014805:Vitamin B 12; D011188:Potassium
Grundzüge der Behandlung von Leberzirrhosen.